JP2015512630A - 急性骨髄性白血病の診断、予後、及び治療用の方法及び組成物 - Google Patents
急性骨髄性白血病の診断、予後、及び治療用の方法及び組成物 Download PDFInfo
- Publication number
- JP2015512630A JP2015512630A JP2015500494A JP2015500494A JP2015512630A JP 2015512630 A JP2015512630 A JP 2015512630A JP 2015500494 A JP2015500494 A JP 2015500494A JP 2015500494 A JP2015500494 A JP 2015500494A JP 2015512630 A JP2015512630 A JP 2015512630A
- Authority
- JP
- Japan
- Prior art keywords
- patient
- mutation
- mll
- dnmt3a
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000031261 Acute myeloid leukaemia Diseases 0.000 title claims abstract description 219
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 title claims abstract description 208
- 238000000034 method Methods 0.000 title claims abstract description 140
- 238000011282 treatment Methods 0.000 title claims abstract description 108
- 238000004393 prognosis Methods 0.000 title abstract description 59
- 238000003745 diagnosis Methods 0.000 title abstract description 15
- 239000000203 mixture Substances 0.000 title description 3
- 230000035772 mutation Effects 0.000 claims abstract description 358
- 230000004083 survival effect Effects 0.000 claims abstract description 168
- 102100024812 DNA (cytosine-5)-methyltransferase 3A Human genes 0.000 claims abstract description 119
- 108010024491 DNA Methyltransferase 3A Proteins 0.000 claims abstract description 116
- 101001109719 Homo sapiens Nucleophosmin Proteins 0.000 claims abstract description 106
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 101
- 102100022678 Nucleophosmin Human genes 0.000 claims abstract description 97
- 101000728236 Homo sapiens Polycomb group protein ASXL1 Proteins 0.000 claims abstract description 77
- 102100029799 Polycomb group protein ASXL1 Human genes 0.000 claims abstract description 77
- 101000653374 Homo sapiens Methylcytosine dioxygenase TET2 Proteins 0.000 claims abstract description 75
- 102100030803 Methylcytosine dioxygenase TET2 Human genes 0.000 claims abstract description 75
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 claims abstract description 70
- 101000692980 Homo sapiens PHD finger protein 6 Proteins 0.000 claims abstract description 68
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 claims abstract description 65
- -1 MLL-PTD Proteins 0.000 claims abstract description 61
- 101000945515 Homo sapiens CCAAT/enhancer-binding protein alpha Proteins 0.000 claims abstract description 58
- 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 claims abstract description 57
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 claims abstract description 56
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 claims abstract description 56
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 claims abstract description 56
- 102100026365 PHD finger protein 6 Human genes 0.000 claims abstract description 50
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims abstract description 48
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims abstract description 46
- 102100039788 GTPase NRas Human genes 0.000 claims abstract description 32
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims abstract description 32
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims abstract description 31
- 108010043471 Core Binding Factor Alpha 2 Subunit Proteins 0.000 claims abstract description 31
- 102100029974 GTPase HRas Human genes 0.000 claims abstract description 31
- 102100030708 GTPase KRas Human genes 0.000 claims abstract description 31
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 claims abstract description 31
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims abstract description 31
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims abstract description 31
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 claims abstract description 31
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 claims abstract description 31
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims abstract description 29
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 claims abstract description 22
- 208000031404 Chromosome Aberrations Diseases 0.000 claims abstract description 14
- 238000007726 management method Methods 0.000 claims abstract description 7
- 102100022103 Histone-lysine N-methyltransferase 2A Human genes 0.000 claims description 61
- 101001045846 Homo sapiens Histone-lysine N-methyltransferase 2A Proteins 0.000 claims description 61
- 230000002559 cytogenic effect Effects 0.000 claims description 58
- 230000005945 translocation Effects 0.000 claims description 54
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 53
- 229960000975 daunorubicin Drugs 0.000 claims description 53
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 53
- 238000002512 chemotherapy Methods 0.000 claims description 51
- 108700020467 WT1 Proteins 0.000 claims description 43
- 101150084041 WT1 gene Proteins 0.000 claims description 43
- 238000002560 therapeutic procedure Methods 0.000 claims description 43
- 238000004458 analytical method Methods 0.000 claims description 41
- 102100022748 Wilms tumor protein Human genes 0.000 claims description 37
- 230000002068 genetic effect Effects 0.000 claims description 37
- 230000001976 improved effect Effects 0.000 claims description 37
- 210000001185 bone marrow Anatomy 0.000 claims description 32
- 230000004044 response Effects 0.000 claims description 32
- 210000004369 blood Anatomy 0.000 claims description 31
- 239000008280 blood Substances 0.000 claims description 31
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 28
- 108020004414 DNA Proteins 0.000 claims description 27
- 230000002411 adverse Effects 0.000 claims description 25
- 210000004027 cell Anatomy 0.000 claims description 25
- 101100243447 Arabidopsis thaliana PER53 gene Proteins 0.000 claims description 20
- 101150080074 TP53 gene Proteins 0.000 claims description 20
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 20
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 19
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 19
- 229960000908 idarubicin Drugs 0.000 claims description 19
- 206010053871 Trisomy 8 Diseases 0.000 claims description 18
- 208000034298 trisomy chromosome 8 Diseases 0.000 claims description 18
- 206010064571 Gene mutation Diseases 0.000 claims description 17
- 210000005087 mononuclear cell Anatomy 0.000 claims description 16
- 239000002246 antineoplastic agent Substances 0.000 claims description 12
- 229940127089 cytotoxic agent Drugs 0.000 claims description 12
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims description 10
- 239000003817 anthracycline antibiotic agent Substances 0.000 claims description 10
- 229960001156 mitoxantrone Drugs 0.000 claims description 8
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 8
- 101150083701 npm1 gene Proteins 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 230000004043 responsiveness Effects 0.000 claims description 8
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 7
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 7
- 229940009456 adriamycin Drugs 0.000 claims description 7
- 229960004679 doxorubicin Drugs 0.000 claims description 7
- 229960001904 epirubicin Drugs 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 101150110046 Dnmt3a gene Proteins 0.000 claims description 6
- 238000012216 screening Methods 0.000 claims description 6
- 239000012453 solvate Substances 0.000 claims description 6
- 101150061453 Cebpa gene Proteins 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 5
- 101150073536 FET3 gene Proteins 0.000 claims description 3
- 230000035899 viability Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 abstract 1
- 101001037292 Triticum aestivum Bowman-Birk type trypsin inhibitor Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 58
- 239000000523 sample Substances 0.000 description 57
- 201000011510 cancer Diseases 0.000 description 41
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 40
- 201000010099 disease Diseases 0.000 description 33
- 238000003556 assay Methods 0.000 description 23
- 230000006698 induction Effects 0.000 description 19
- 208000032839 leukemia Diseases 0.000 description 19
- 238000012360 testing method Methods 0.000 description 17
- 238000013517 stratification Methods 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 15
- 206010069754 Acquired gene mutation Diseases 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 210000000265 leukocyte Anatomy 0.000 description 12
- 230000037439 somatic mutation Effects 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 108700028369 Alleles Proteins 0.000 description 8
- 101710177984 Isocitrate dehydrogenase [NADP] Proteins 0.000 description 8
- 101710102690 Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 description 8
- 101710175291 Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 description 8
- 101710157228 Isoepoxydon dehydrogenase patN Proteins 0.000 description 8
- 230000005856 abnormality Effects 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 208000025113 myeloid leukemia Diseases 0.000 description 8
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 7
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 7
- 230000034994 death Effects 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000009093 first-line therapy Methods 0.000 description 7
- 238000007619 statistical method Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 238000007473 univariate analysis Methods 0.000 description 7
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 6
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 208000037516 chromosome inversion disease Diseases 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 208000003747 lymphoid leukemia Diseases 0.000 description 6
- 230000003211 malignant effect Effects 0.000 description 6
- 238000001959 radiotherapy Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 238000010200 validation analysis Methods 0.000 description 6
- 102000006990 Core Binding Factors Human genes 0.000 description 5
- 108010072732 Core Binding Factors Proteins 0.000 description 5
- 238000012408 PCR amplification Methods 0.000 description 5
- 230000000735 allogeneic effect Effects 0.000 description 5
- 230000000692 anti-sense effect Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 201000005787 hematologic cancer Diseases 0.000 description 5
- 230000002489 hematologic effect Effects 0.000 description 5
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000007901 in situ hybridization Methods 0.000 description 5
- 238000002493 microarray Methods 0.000 description 5
- 238000000491 multivariate analysis Methods 0.000 description 5
- 230000000869 mutational effect Effects 0.000 description 5
- 238000011476 stem cell transplantation Methods 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- 238000004820 blood count Methods 0.000 description 4
- 210000002798 bone marrow cell Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000002349 favourable effect Effects 0.000 description 4
- 238000012252 genetic analysis Methods 0.000 description 4
- 230000007614 genetic variation Effects 0.000 description 4
- 239000002679 microRNA Substances 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 239000013615 primer Substances 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 206010000830 Acute leukaemia Diseases 0.000 description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108700011259 MicroRNAs Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 238000000546 chi-square test Methods 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000003394 haemopoietic effect Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000001325 log-rank test Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000007480 sanger sequencing Methods 0.000 description 3
- 230000000392 somatic effect Effects 0.000 description 3
- 238000011272 standard treatment Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 206010006002 Bone pain Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- 238000000729 Fisher's exact test Methods 0.000 description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 208000037280 Trisomy Diseases 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 230000036978 cell physiology Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 230000005861 gene abnormality Effects 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000011368 intensive chemotherapy Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000036438 mutation frequency Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 239000002773 nucleotide Chemical group 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 238000009522 phase III clinical trial Methods 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 102200116484 rs121913502 Human genes 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 238000011301 standard therapy Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- UDPGUMQDCGORJQ-UHFFFAOYSA-N (2-chloroethyl)phosphonic acid Chemical compound OP(O)(=O)CCCl UDPGUMQDCGORJQ-UHFFFAOYSA-N 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 102100032249 Dystonin Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 241000209027 Ilex aquifolium Species 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 238000001358 Pearson's chi-squared test Methods 0.000 description 1
- 238000012952 Resampling Methods 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 238000011366 aggressive therapy Methods 0.000 description 1
- 238000011256 aggressive treatment Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000009108 consolidation therapy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 238000004690 coupled electron pair approximation Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000012953 feeding on blood of other organism Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000009033 hematopoietic malignancy Effects 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical group CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000010202 multivariate logistic regression analysis Methods 0.000 description 1
- 210000001167 myeloblast Anatomy 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 238000003499 nucleic acid array Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011867 re-evaluation Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 239000002924 silencing RNA Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000009120 supportive therapy Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261609723P | 2012-03-12 | 2012-03-12 | |
| US61/609,723 | 2012-03-12 | ||
| PCT/US2013/030208 WO2013138237A1 (en) | 2012-03-12 | 2013-03-11 | Methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015512630A true JP2015512630A (ja) | 2015-04-30 |
| JP2015512630A5 JP2015512630A5 (enExample) | 2016-05-12 |
Family
ID=49161688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015500494A Pending JP2015512630A (ja) | 2012-03-12 | 2013-03-11 | 急性骨髄性白血病の診断、予後、及び治療用の方法及び組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20150031641A1 (enExample) |
| EP (1) | EP2825669A4 (enExample) |
| JP (1) | JP2015512630A (enExample) |
| CN (1) | CN104508143A (enExample) |
| AU (1) | AU2013232379A1 (enExample) |
| CA (1) | CA2867375A1 (enExample) |
| WO (1) | WO2013138237A1 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101877607B1 (ko) * | 2016-03-03 | 2018-07-12 | 포항공과대학교 산학협력단 | 인슐린／ｉｇｆ―1 수용체 결핍 돌연변이체의 발달결함만 특이적으로 억제된 예쁜꼬마선충 |
| JP2019507721A (ja) * | 2015-12-04 | 2019-03-22 | アジオス ファーマシューティカルズ， インコーポレイテッド | 悪性腫瘍の処置の方法 |
| JP2023521927A (ja) * | 2020-07-30 | 2023-05-25 | ソウル大学校産学協力団 | Ｐｈｆ６を標的にするヒストンｈ２ｂエピジェネティクスス調節剤スクリーニング方法 |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220070066A (ko) | 2014-03-14 | 2022-05-27 | 아지오스 파마슈티컬스 아이엔씨. | 치료적으로 활성인 화합물의 약제학적 조성물 |
| EP3224380A1 (en) | 2014-11-25 | 2017-10-04 | The Broad Institute Inc. | Clonal haematopoiesis |
| EP3626832B1 (en) | 2014-11-25 | 2024-06-12 | The Brigham and Women's Hospital, Inc. | Method of identifying a person having a predisposition to or afflicted with a cardiometabolic disease |
| CN104774954A (zh) * | 2015-04-23 | 2015-07-15 | 上海允英医疗科技有限公司 | 用于hras突变检测的引物、探针及检测试剂盒 |
| PT3362065T (pt) | 2015-10-15 | 2024-06-21 | Servier Lab | Terapia de combinação compreendendo ivosidenib, citarabina e daunorubicina ou idarubicina para o tratamento de leucemia mielóide aguda |
| US10653710B2 (en) | 2015-10-15 | 2020-05-19 | Agios Pharmaceuticals, Inc. | Combination therapy for treating malignancies |
| MX2018005771A (es) * | 2015-11-11 | 2019-03-14 | Celator Pharmaceuticals Inc | Ensayos y metodos para seleccionar un regimen de tratamiento para un sujeto con leucemia. |
| WO2017084027A1 (zh) * | 2015-11-17 | 2017-05-26 | 安诺优达基因科技(北京)有限公司 | 一种用于急性髓细胞白血病预后分层的试剂盒及检测方法 |
| CN105861674A (zh) * | 2016-04-27 | 2016-08-17 | 上海荻硕贝肯生物科技有限公司 | 用于检测与aml预后相关的基因突变的引物、试剂盒及方法 |
| CN105969892B (zh) * | 2016-07-14 | 2019-07-19 | 北京大学人民医院 | Csrp2在作为评估成人b-all患者预后风险标记物中的应用 |
| CN106381332A (zh) * | 2016-08-31 | 2017-02-08 | 天津协和华美医学诊断技术有限公司 | 一种检测aml相关基因群的检测试剂盒 |
| AU2017353925A1 (en) * | 2016-11-02 | 2018-09-27 | Arog Pharmaceuticals, Inc. | Crenolanib for treating FLT3 mutated proliferative disorders associated mutations |
| CN107641650B (zh) * | 2017-08-24 | 2020-05-08 | 中国人民解放军总医院 | Nr1h3在急性髓系白血病精准靶向检测及预后评估中的应用 |
| US10460446B2 (en) * | 2017-10-16 | 2019-10-29 | Nant Holdings Ip, Llc | Image-based circular plot recognition and interpretation |
| CN107841556B (zh) * | 2017-12-19 | 2020-12-01 | 武汉大学 | 一种基于C/EBPα和IGF1R基因筛选药物发育毒性的试剂盒及应用 |
| CN107893118A (zh) * | 2017-12-25 | 2018-04-10 | 合肥艾迪康临床检验所有限公司 | 检测phf6点突变的方法和引物 |
| US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
| CN109172597B (zh) * | 2018-09-06 | 2020-12-18 | 清华大学深圳研究生院 | 调节rDNA基因染色质组蛋白甲基化水平的物质及其应用 |
| CN110124038A (zh) * | 2019-05-08 | 2019-08-16 | 山东大学齐鲁医院 | 腺苷酸琥珀酸合成酶基因和/或其编码的蛋白的新应用 |
| WO2021209517A1 (en) * | 2020-04-15 | 2021-10-21 | Centre National De La Recherche Scientifique | Prognosis method of acute myeloid leukaemia |
| CN111560438B (zh) * | 2020-06-11 | 2024-01-19 | 迈杰转化医学研究(苏州)有限公司 | 检测aml预后相关基因突变的引物组合物、试剂盒及其应用 |
| CN112708675A (zh) * | 2020-12-25 | 2021-04-27 | 中山大学肿瘤防治中心 | 骨髓nk细胞联合mcl1抑制剂在抗白血病中的应用 |
| CN112626215B (zh) * | 2020-12-30 | 2023-03-24 | 武汉康圣达医学检验所有限公司 | Aml预后相关基因表达检测试剂盒 |
| CN115216541A (zh) * | 2021-04-15 | 2022-10-21 | 复旦大学附属华山医院 | 一组白血病标志物及应用 |
| CN113764038B (zh) * | 2021-08-31 | 2023-08-22 | 华南理工大学 | 构建骨髓增生异常综合征转白基因预测模型的方法 |
| CN115323051B (zh) * | 2022-02-22 | 2023-04-07 | 天津见康华美医学诊断技术有限公司 | 一种急性髓系白血病检测探针组合物及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5919623A (en) * | 1994-04-27 | 1999-07-06 | St. James's And Seacroft University Hospitals Nhs Trust | Nucleic acid mutation assays |
| JP5937520B2 (ja) * | 2010-02-12 | 2016-06-22 | イプソゲン | 骨髄性腫瘍の新規診断マーカーとしてのａｓｘｌ１ |
| JP6054303B2 (ja) * | 2010-12-30 | 2016-12-27 | ファウンデーション メディシン インコーポレイテッドＦｏｕｎｄａｔｉｏｎ Ｍｅｄｉｃｉｎｅ， Ｉｎｃ． | 腫瘍試料の多重遺伝子分析の最適化 |
-
2013
- 2013-03-11 AU AU2013232379A patent/AU2013232379A1/en not_active Abandoned
- 2013-03-11 JP JP2015500494A patent/JP2015512630A/ja active Pending
- 2013-03-11 US US14/384,580 patent/US20150031641A1/en not_active Abandoned
- 2013-03-11 CN CN201380024896.0A patent/CN104508143A/zh active Pending
- 2013-03-11 WO PCT/US2013/030208 patent/WO2013138237A1/en not_active Ceased
- 2013-03-11 EP EP13760340.3A patent/EP2825669A4/en not_active Withdrawn
- 2013-03-11 CA CA2867375A patent/CA2867375A1/en not_active Abandoned
Non-Patent Citations (3)
| Title |
|---|
| JPN6017000433; Ｔｈｅ Ｈｅｍａｔｏｌｏｇｙ Ｊｏｕｒｎａｌ， ２００３， Ｖｏｌ． ４， Ｎｏ． １， ｐｐ． ３１-４０ * |
| JPN6017000434; ＢＬＯＯＤ， ２０１１， Ｖｏｌ． １１８， Ｎｏ． ２０， ｐｐ． ５５９３-５６０３ * |
| JPN6017000436; ＢＬＯＯＤ， ２０１１， Ｖｏｌ． １１８， Ｎｏ． １４， ｐｐ． ３８０３-３８１０ * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019507721A (ja) * | 2015-12-04 | 2019-03-22 | アジオス ファーマシューティカルズ， インコーポレイテッド | 悪性腫瘍の処置の方法 |
| KR101877607B1 (ko) * | 2016-03-03 | 2018-07-12 | 포항공과대학교 산학협력단 | 인슐린／ｉｇｆ―1 수용체 결핍 돌연변이체의 발달결함만 특이적으로 억제된 예쁜꼬마선충 |
| JP2023521927A (ja) * | 2020-07-30 | 2023-05-25 | ソウル大学校産学協力団 | Ｐｈｆ６を標的にするヒストンｈ２ｂエピジェネティクスス調節剤スクリーニング方法 |
| JP7501879B2 (ja) | 2020-07-30 | 2024-06-18 | ソウル大学校産学協力団 | Ｐｈｆ６を標的にするヒストンｈ２ｂエピジェネティクスス調節剤スクリーニング方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2867375A1 (en) | 2013-09-19 |
| AU2013232379A1 (en) | 2014-09-25 |
| CN104508143A (zh) | 2015-04-08 |
| EP2825669A4 (en) | 2016-02-24 |
| US20150031641A1 (en) | 2015-01-29 |
| WO2013138237A9 (en) | 2015-01-29 |
| EP2825669A1 (en) | 2015-01-21 |
| WO2013138237A1 (en) | 2013-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015512630A (ja) | 急性骨髄性白血病の診断、予後、及び治療用の方法及び組成物 | |
| EP3198026B1 (en) | Method of determining pik3ca mutational status in a sample | |
| EP2546365B1 (en) | Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma | |
| US10982286B2 (en) | Algorithmic approach for determining the plasma genome abnormality PGA and the urine genome abnormality UGA scores based on cell free cfDNA copy number variations in plasma and urine | |
| Wang et al. | A six gene expression signature defines aggressive subtypes and predicts outcome in childhood and adult acute lymphoblastic leukemia | |
| US10711308B2 (en) | Mutation signatures for predicting the survivability of myelodysplastic syndrome subjects | |
| AU2013353839A1 (en) | Molecular diagnostic test for cancer | |
| AU2009238613A1 (en) | Gene expression profiling based identification of genomic signature of high-risk multiple myeloma and uses thereof | |
| JP2011512785A (ja) | ファルネシルトランスフェラーゼ治療に対する急性骨髄性白血病応答を決定する方法 | |
| AU2017228649A1 (en) | Methods for predicting drug responsiveness in cancer patients | |
| JP2011509689A (ja) | Ｉｉ及びｉｉｉ期結腸癌の分子病期分類並びに予後診断 | |
| US20160024591A1 (en) | Methods and compositions for correlating genetic markers with risk of aggressive prostate cancer | |
| WO2017132749A1 (en) | Method for identifying high-risk aml patients | |
| CN111194356B (zh) | 用于检测浆细胞恶病质的方法 | |
| US20060141504A1 (en) | Molecular technologies for improved risk classification and therapy for acute lymphoblastic leukemia in children and adults | |
| Gouda et al. | Pathogenetic Significance of YBX1 Expression in Acute Myeloid Leukemia Relapse | |
| Hasan et al. | Over expression of brain and acute leukemia, cytoplasmic and ETS‐related gene is associated with poor outcome in acute myeloid leukemia | |
| JP2014501496A (ja) | 消化管間質腫瘍における臨床転帰のシグネチャーおよび消化管間質腫瘍の治療の方法 | |
| KR102573028B1 (ko) | Mphosph9의 단일염기다형성을 이용한 소세포폐암의 예후 진단방법 | |
| KR102901130B1 (ko) | 대규모 코호트 유래 전장 유전체 연관 분석 및 dna 메틸화 분석을 이용한 간 섬유화 진단용 바이오마커 조성물 | |
| KR102573077B1 (ko) | Mff의 단일염기다형성을 이용한 소세포폐암의 예후 진단방법 | |
| WO2012088146A2 (en) | Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease | |
| EP3411517B1 (en) | Method for identifying high-risk aml patients | |
| CN120866519A (zh) | 用于肺癌免疫治疗适用性的检测系统及方法 | |
| HK40030202A (en) | Methods for detection of plasma cell dyscrasia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20160311 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160311 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170117 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170905 |